Truist Financial Corp trimmed its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 39.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,557 shares of the company's stock after selling 17,619 shares during the quarter. Truist Financial Corp's holdings in Genmab A/S were worth $575,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. ABC Arbitrage SA purchased a new stake in shares of Genmab A/S in the 4th quarter valued at approximately $3,692,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Genmab A/S by 229.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock valued at $1,033,000 after purchasing an additional 34,652 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after buying an additional 827 shares during the period. R Squared Ltd purchased a new position in shares of Genmab A/S during the fourth quarter valued at $93,000. Finally, Blue Trust Inc. raised its position in Genmab A/S by 33.4% during the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after buying an additional 1,442 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have commented on GMAB. BMO Capital Markets restated an "outperform" rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $42.17.
Get Our Latest Report on GMAB
Genmab A/S Stock Performance
Shares of NASDAQ:GMAB traded down $0.46 on Thursday, hitting $23.64. 352,538 shares of the company were exchanged, compared to its average volume of 855,822. The company's 50 day moving average price is $21.16 and its two-hundred day moving average price is $22.71. The firm has a market capitalization of $15.64 billion, a price-to-earnings ratio of 13.58, a PEG ratio of 2.65 and a beta of 0.98. Genmab A/S has a one year low of $18.64 and a one year high of $31.88.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.
Genmab A/S Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
